Jessie Chen (She/Her)
About Jessie Chen (She/Her)
Jessie Chen is an Associate Scientist I at Asher Biotherapeutics, where she has worked since 2021, focusing on biotherapeutic development. She has a background in molecular biology and has held various research and teaching roles, including positions at American Gene Technologies and the University of Washington.
Work at Asher Biotherapeutics
Jessie Chen has been employed at Asher Biotherapeutics as an Associate Scientist I since 2021. In this role, she focuses on biotherapeutic development and contributes to various research projects. Her work is instrumental in advancing the company's objectives in the biotherapeutics sector. She has been part of initiatives that aim to enhance the efficacy and safety of therapeutic agents.
Previous Experience in Research
Prior to her current position, Jessie Chen worked at RubrYc Therapeutics, Inc. as an Associate Researcher for six months in 2020. She also served as an Undergraduate Teaching Assistant at the University of Washington from 2018 to 2020, where she supported educational activities in the field of molecular biology. Additionally, she completed a three-year internship at American Gene Technologies International Inc. from 2015 to 2018.
Education and Expertise
Jessie Chen earned her Bachelor of Science degree in Cell/Cellular and Molecular Biology from the University of Washington, completing her studies from 2016 to 2020. Her academic background provides a strong foundation for her work in biotherapeutics. She has engaged in professional development activities to enhance her expertise in this area, demonstrating a commitment to continuous learning.
Research Contributions and Presentations
Jessie Chen has participated in collaborative research initiatives that focus on advancing molecular biology techniques. She contributed to research on the CD8+ T cell selectivity of AB248, which is critical for ensuring optimal anti-tumor activity and safety in nonclinical models. Her research efforts were presented at the Society for Immunotherapy of Cancer (SITC) in November 2022, showcasing her contributions to the field.